Both Europe and Japan have rejected the US's continuations approach
I came across a very interesting perspective on the US claims and continuations debate posted on Holman’s Biotech IP Blog. Basically, it seems to be saying that the JPO and the EPO have had cause to look at claims and continuations in recent years,…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now